Getting to know Favipiravir

Getting to know Favipiravir

From today, favipiravir will investigate in the UK as part of the Platform Randomised trial of Interventions against COVID-19 In older peoPLE (PRINCIPLE), the world’s largest clinical trial of possible COVID-19 treatments for recovery at home and in other non-hospital settings.

Led by University of Oxford researchers, PRINCIPLE is one of the UK Government’s national priority platform trials for COVID-19 treatments. Was set-up with the intention. That drugs shown to have a clinical benefit could be rapidly introduced into routine NHS care.

Favipiravir is a drug in the formula for สมัครสมาชิก UFABET วันนี้ รับเครดิตฟรีทุกวัน treating COVID patients in Thailand. Previously, this drug was use to treat influenza. Later, it was found. That it can applie to treat COVID patients. It works in 2 ways:

1. Inhibit the growth of viruses
2. It causes the virus to mutate, meaning. That the drug will inhibit the enzyme RNA-dependent RNA polymerase, RdRP. Which is enzyme found only in viruses. When the drug enters the body. It is change into active form. Causing the virus to mutate until the body’s immune system can eliminate the virus completely or leave a small amount that cannot cause disease in the body anymore.

Patients who will receive Favipiravir

The Department of Medical Services, Ministry of Public Health has set guidelines for treating COVID patients with Favipiravir as follows:

1. Patients with mild, non-severe symptoms and no pneumonia, the doctor will consider giving medication as soon as possible because this medication is effective for this group of patients. However, if the infection has found for more than 7 days. The patient tends to recover on their own without complications, so there is no need to use additional medication.
2. For patients with no symptoms or only mild symptoms, who are at risk of severe disease, the doctor will consider giving the drug for 5 days, depending on the symptoms.
3. Patients with severe symptoms, pulmonary edema, or reduced blood oxygen levels: These patients will receive medication for 5 to 10 days, depending on their symptoms.

The trial has so far found that the antibiotics azithromycin and doxycycline are not generally effective as treatments during the early stages of COVID-19, with implications for how COVID-19 illness is treated both in the UK and internationally.